Program
lonapegsomatropin
Also written as “Lonapegsomatropin”, “Dual therapy with navepegritide and lonapegsomatropin” and “Lonapegsomatropin [SKYTROFA®]”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Achondroplasia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ascendis Pharma Endocrinology Division | 31 open or running | phase 3since Oct 29, 2020 | Oct 29, 2020 | none ahead |
| Ascendis Pharma | 22 open or running | phase 3since Oct 14, 2025 | Oct 14, 2025 | Feb 2028phase 3 · NCT07221851 |
| Visen Pharmaceuticals (Shanghai) | 10 open or running | phase 3since Mar 26, 2020 | Mar 26, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2020First study: phase 3 study in Dwarfism, PituitaryNew to Visen Pharmaceuticals (Shanghai)Visen Pharmaceuticals (Shanghai) · NCT04326374 · 150 enrolled · China
- Oct 29, 2020Ascendis Pharma Endocrinology Division’s first study: phase 3 study in Dwarfism, PituitaryNew to Ascendis Pharma Endocrinology DivisionAscendis Pharma Endocrinology Division · NCT04615273 · 264 enrolled · United States, Armenia, Australia and more
- Sep 24, 2021Phase 3 study in Dwarfism, PituitaryAscendis Pharma Endocrinology Division · NCT05171855 · 220 enrolled · United States, Armenia, Australia and more
- Jan 10, 2023Phase 2 study in Turner SyndromeAscendis Pharma Endocrinology Division · NCT05690386 · 48 enrolled · United States
- Oct 14, 2025Ascendis Pharma’s first study: phase 3 study in Turner SyndromeNew to Ascendis PharmaAscendis Pharma · NCT07221851 · 186 planned · United States, France, Germany and more
- Oct 30, 2026Phase 3 study in AchondroplasiaAscendis Pharma · NCT07924059 · 144 planned
Ahead
- Feb 2028Primary completion: phase 3 study in Turner SyndromeAscendis Pharma · NCT07221851
- Sep 2028Primary completion: phase 3 study in AchondroplasiaAscendis Pharma · NCT07924059
TargetBeta
“Growth hormone receptor agonist”ChEMBL 37, by rule
Other programs on GHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Human Growth Hormonerule | Novo Nordisk | phase 4 | 118 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07924059Achondroplasia | 3 | Not yet recruiting | Ascendis Pharma | Sep 2028 | 144 |
| NCT07221851Turner Syndrome · United States, France, Germany and more | 3 | Recruiting | Ascendis Pharma | Feb 2028 | 186 |
| NCT05690386Turner Syndrome · United States | 2 | Active, not recruiting | Ascendis Pharma Endocrinology Division | Oct 18, 2024 | 48 |
| NCT05171855Dwarfism, Pituitary · United States, Armenia, Australia and more | 3 | Completed | Ascendis Pharma Endocrinology Division | Dec 23, 2024 | 220 |
| NCT04615273Dwarfism, Pituitary · United States, Armenia, Australia and more | 3 | Completed | Ascendis Pharma Endocrinology Division | Nov 2, 2023 | 264 |
| NCT04326374Dwarfism, Pituitary · China | 3 | UNKNOWN | Visen Pharmaceuticals (Shanghai) | Apr 2022 | 150 |
How it is read
Names in the registry
- “Lonapegsomatropin”, 3 entries
- “Dual therapy with navepegritide and lonapegsomatropin”, 1 entry
- “Lonapegsomatropin [SKYTROFA®]”, 1 entry
- “TransCon hGH”, 1 entry
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 3 studies
- Turner Syndrome, 2 studies
- Achondroplasia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.